dpp 4 inhibitor glp 1 agonist GLP-1 Receptor Agonists Have better Outcomes Than DPP4 Inhibitors in T2D patients & CKD Clinical Use of DPP-4 Inhibitors

Bottom row: 24-2 Humphrey visual fields grey scale and pattern deviation from 1-year follow-up

Its titration schedule is as follows: Week 1 (starting dose) : 0.6 mg per day Week 2: 1.2 mg per day Week 3: 1.8 mg per day Week 4: 2.4 mg per day Week 5 and onwards : 3 mg per day (therapeutic or maintenance dose) Rybelsus (semaglutide) daily oral dosing schedule Rybelsus comes in two formulations: R1 and R2

[DOI] [PMC free article] [PubMed] [Google Scholar] 85.El-Boghdadly K., Dhesi J., Fabb P., et al

Imbalance after matching was assessed based on a standardized mean difference threshold of 0.2 (Supplementary Fig

These medications include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GIP/GLP-1 receptor agonist with a slightly different mechanism

Acknowledgments The authors gratefully acknowledge the critical reviews and insights of Sarah Armstrong MD, Nancie MacIver MD PhD, and Lisa Rasbach PhD CPNP